Cost of Revenue Trends: Amgen Inc. vs Supernus Pharmaceuticals, Inc.

Amgen vs Supernus: A Decade of Cost Dynamics

__timestampAmgen Inc.Supernus Pharmaceuticals, Inc.
Wednesday, January 1, 201444220000005758000
Thursday, January 1, 201542270000008423000
Friday, January 1, 2016416200000011986000
Sunday, January 1, 2017406900000015215000
Monday, January 1, 2018410100000015356000
Tuesday, January 1, 2019435600000016660000
Wednesday, January 1, 2020615900000052459000
Friday, January 1, 2021645400000075061000
Saturday, January 1, 2022640600000087221000
Sunday, January 1, 2023841500000083779000
Monday, January 1, 202412858000000
Loading chart...

Infusing magic into the data realm

Cost of Revenue Trends: Amgen Inc. vs Supernus Pharmaceuticals, Inc.

In the ever-evolving pharmaceutical industry, understanding cost dynamics is crucial. Over the past decade, Amgen Inc. and Supernus Pharmaceuticals, Inc. have showcased contrasting trends in their cost of revenue. From 2014 to 2023, Amgen's cost of revenue surged by approximately 90%, reflecting its expansive growth and increased production capabilities. In contrast, Supernus Pharmaceuticals, Inc. experienced a more modest increase of around 1,350%, albeit from a much smaller base, highlighting its rapid scaling efforts.

Key Insights

  • Amgen Inc.: Starting at 4.4 billion in 2014, Amgen's cost of revenue peaked at 8.4 billion in 2023, indicating robust growth and market expansion.
  • Supernus Pharmaceuticals, Inc.: Despite starting with a modest 5.8 million in 2014, Supernus reached 87.2 million by 2023, showcasing its aggressive growth strategy.

These trends underscore the diverse strategies and market positions of these pharmaceutical giants.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025